Last reviewed · How we verify

Recaticimab and Statin — Competitive Intelligence Brief

Recaticimab and Statin (Recaticimab and Statin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor. Area: Cardiovascular / Immunology.

marketed IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor IL-6 receptor / HMG-CoA reductase Cardiovascular / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Recaticimab and Statin (Recaticimab and Statin) — Peking Union Medical College Hospital. Recaticimab is a monoclonal antibody that inhibits IL-6 signaling to reduce inflammation, combined with a statin to manage lipid levels and provide cardiovascular protection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Recaticimab and Statin TARGET Recaticimab and Statin Peking Union Medical College Hospital marketed IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor IL-6 receptor / HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-6 inhibitor monoclonal antibody + HMG-CoA reductase inhibitor class)

  1. Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recaticimab and Statin — Competitive Intelligence Brief. https://druglandscape.com/ci/recaticimab-and-statin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: